{"id":359,"date":"2020-08-20T14:09:20","date_gmt":"2020-08-20T13:09:20","guid":{"rendered":"https:\/\/www.sedapds.com\/?p=359"},"modified":"2023-02-16T15:09:03","modified_gmt":"2023-02-16T15:09:03","slug":"pharmaceutical-analysis-new-uhplc","status":"publish","type":"post","link":"https:\/\/www.sedapds.com\/news\/pharmaceutical-analysis-new-uhplc\/","title":{"rendered":"Pharmaceutical Analysis: New UHPLC enhances our offering"},"content":{"rendered":"\r\n<p>Seda&#8217;s latest acquisition &#8211; a shiny new UHPLC (<a href=\"https:\/\/www.agilent.com\/en\/product\/liquid-chromatography\/hplc-systems\/analytical-hplc-systems\/1290-infinity-ii-lc-system\" target=\"_blank\" rel=\"noopener\">Agilent 1290 Infinity II<\/a>) expanding our capabilities in pharmaceutical analysis and enabling rapid and reliable data generation for Clients.<\/p>\r\n<p>The 1290 Infinity II LC System is an ultra-high performance liquid chromatography instrument (UHPLC)\u00a0 designed to be both a HPLC and high-end UHPLC system in a single flow path.<\/p>\r\n<p>Our extensive analytical capabilities and suite of in-house analytical instrumentation allow us to support a range of CMC activities extending from early phase method development stability studies and impurity analysis, through to excipient compatibility studies and understanding product formulation and behaviour. The increasing complexity of pharmaceutical compounds encountered today requires a deep understanding of analytical techniques which we apply to solve the most challenging of problems.<\/p>\r\n<p>Seda\u2019s laboratories can be used as a standalone service which delivers the \u2018nuts and bolts\u2019 of data generation. Alternatively, it can be combined with our\u00a0<a href=\"https:\/\/www.sedapds.com\/services\/consultancy-services\/\" target=\"_blank\" rel=\"noopener\">drug product consulting<\/a>\u00a0service to provide the additional advantage of seamless integration of the experimental plan with top end Strategy, Interpretation and Execution which can maximise value build and speed of development.<\/p>\r\n<ul>\r\n<li>Our laboratory services include:<\/li>\r\n<li>Physicochemical characterisation and preformulation services<\/li>\r\n<li>Pharmaceutical analysis<\/li>\r\n<li>Analytical method development and verification<\/li>\r\n<li>Chemical and physical stability studies<\/li>\r\n<li>Preclinical efficacy and safety study formulation development (with a special focus on challenging molecules)<\/li>\r\n<li>First-in-Human formulation prototyping<\/li>\r\n<li>Pharmaceutical development activities<\/li>\r\n<li>Later phase \/ commercial formulation prototyping<\/li>\r\n<li>Biorelevant dissolution and development of\u00a0<a href=\"https:\/\/doi.org\/10.3390\/pharmaceutics14051010\" target=\"_blank\" rel=\"noopener\">clinically relevant dissolution tests<\/a><\/li>\r\n<li>Enabling formulations and specialist drug delivery technology selection<\/li>\r\n<\/ul>\r\n<p>Find out more about the <a href=\"https:\/\/www.sedapds.com\/services\/laboratory-services\/\" target=\"_blank\" rel=\"noopener\">laboratory\u00a0services<\/a> we can offer.<\/p>\r\n<p>&nbsp;<\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>Seda&#8217;s latest acquisition &#8211; a shiny new UHPLC (Agilent 1290 Infinity II) expanding our capabilities in pharmaceutical analysis and enabling rapid and reliable data generation for Clients. The 1290 Infinity II LC System is an ultra-high performance liquid chromatography instrument (UHPLC)\u00a0 designed to be both a HPLC and high-end UHPLC system in a single flow&#8230;<\/p>\n","protected":false},"author":1,"featured_media":360,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"categories":[1],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v15.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<meta name=\"description\" content=\"Seda acquires new UHPLC (Agilent infinity II) - expanding our capability in pharmaceutical analysis, enabling rapid data generation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sedapds.com\/news\/pharmaceutical-analysis-new-uhplc\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmaceutical Analysis: New UHPLC enhances our offering | Seda\" \/>\n<meta property=\"og:description\" content=\"Seda acquires new UHPLC (Agilent infinity II) - expanding our capability in pharmaceutical analysis, enabling rapid data generation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sedapds.com\/news\/pharmaceutical-analysis-new-uhplc\/\" \/>\n<meta property=\"og:site_name\" content=\"Seda\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-20T13:09:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-16T15:09:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sedapds.com\/wp-content\/uploads\/2020\/12\/analytical-capability.png\" \/>\n\t<meta property=\"og:image:width\" content=\"391\" \/>\n\t<meta property=\"og:image:height\" content=\"391\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@sedapds\" \/>\n<meta name=\"twitter:site\" content=\"@sedapds\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\">\n\t<meta name=\"twitter:data1\" content=\"1 minute\">\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.sedapds.com\/#website\",\"url\":\"https:\/\/www.sedapds.com\/\",\"name\":\"Seda\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":\"https:\/\/www.sedapds.com\/?s={search_term_string}\",\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.sedapds.com\/news\/pharmaceutical-analysis-new-uhplc\/#primaryimage\",\"inLanguage\":\"en-GB\",\"url\":\"https:\/\/www.sedapds.com\/wp-content\/uploads\/2020\/12\/analytical-capability.png\",\"width\":391,\"height\":391,\"caption\":\"UHPLC instrument\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.sedapds.com\/news\/pharmaceutical-analysis-new-uhplc\/#webpage\",\"url\":\"https:\/\/www.sedapds.com\/news\/pharmaceutical-analysis-new-uhplc\/\",\"name\":\"Pharmaceutical Analysis: New UHPLC enhances our offering | Seda\",\"isPartOf\":{\"@id\":\"https:\/\/www.sedapds.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.sedapds.com\/news\/pharmaceutical-analysis-new-uhplc\/#primaryimage\"},\"datePublished\":\"2020-08-20T13:09:20+00:00\",\"dateModified\":\"2023-02-16T15:09:03+00:00\",\"author\":{\"@id\":\"https:\/\/www.sedapds.com\/#\/schema\/person\/20a838df283dd686dd27e29b45644b62\"},\"description\":\"Seda acquires new UHPLC (Agilent infinity II) - expanding our capability in pharmaceutical analysis, enabling rapid data generation.\",\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.sedapds.com\/news\/pharmaceutical-analysis-new-uhplc\/\"]}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.sedapds.com\/#\/schema\/person\/20a838df283dd686dd27e29b45644b62\",\"name\":\"platform81\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.sedapds.com\/#personlogo\",\"inLanguage\":\"en-GB\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/345bf6d4bd86bf717b7958a293841cb3?s=96&d=mm&r=g\",\"caption\":\"platform81\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","_links":{"self":[{"href":"https:\/\/www.sedapds.com\/wp-json\/wp\/v2\/posts\/359"}],"collection":[{"href":"https:\/\/www.sedapds.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sedapds.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sedapds.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sedapds.com\/wp-json\/wp\/v2\/comments?post=359"}],"version-history":[{"count":7,"href":"https:\/\/www.sedapds.com\/wp-json\/wp\/v2\/posts\/359\/revisions"}],"predecessor-version":[{"id":1776,"href":"https:\/\/www.sedapds.com\/wp-json\/wp\/v2\/posts\/359\/revisions\/1776"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sedapds.com\/wp-json\/wp\/v2\/media\/360"}],"wp:attachment":[{"href":"https:\/\/www.sedapds.com\/wp-json\/wp\/v2\/media?parent=359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sedapds.com\/wp-json\/wp\/v2\/categories?post=359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sedapds.com\/wp-json\/wp\/v2\/tags?post=359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}